The first CAR-T clinical trial for CRC, which began in 2014, studied the safety and efficacy of second-generation CEA-CAR T cells in patients with CRC, and also included patients with lung, stomach, breast, and pancreatic cancers (NCT02349724) [87]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.